#1 Clinical Trials Search in Europe

Flupentixol Decanoate

This article explores various clinical trials investigating the use of Flupentixol Decanoate, a medication with potential applications in treating substance-related disorders and emotional conditions. The trials cover a range of topics, including its efficacy in methamphetamine addiction, emotional disorders, and bioequivalence studies comparing different formulations. These studies aim to provide valuable insights into the safety, effectiveness, and optimal dosing of Flupentixol Decanoate for various medical conditions.

Table of Contents

What is Flupentixol Decanoate?

Flupentixol Decanoate is a medication that belongs to a class of drugs known as antipsychotics. It is also known by its brand name Fluanxol®[4]. This medication is used to treat various mental health conditions and has been the subject of several clinical trials to evaluate its effectiveness and safety.

Uses of Flupentixol Decanoate

Flupentixol Decanoate is primarily used to treat the following conditions:

  • Substance-Related Disorders: One of the main uses of Flupentixol Decanoate is in the treatment of substance-related disorders, particularly methamphetamine dependence. A clinical trial was conducted to evaluate its safety and efficacy in treating methamphetamine addiction[1].
  • Emotional Disorders: While not directly mentioned for Flupentixol Decanoate, a related compound (Flupentixol combined with Melitracen) has been studied for its effectiveness in treating emotional disorders, including involuntary emotional expression disorder (IEED)[2].
  • Depression and Anxiety: In low doses, Flupentixol has been found to have antidepressant and anti-anxiety effects[2].

Different Formulations

Flupentixol is available in various formulations, each designed for specific purposes:

  • Flupentixol Decanoate: This is a long-acting injectable form of the medication, often used for maintenance treatment[1].
  • Film-coated tablets: A new formulation that has been developed and tested for bioequivalence with the existing coated tablets[4].
  • Coated tablets: The traditional oral formulation, available in various strengths (0.5 mg, 1 mg, and 5 mg)[4].

Bioequivalence Studies

Bioequivalence studies are conducted to ensure that different formulations of a medication have the same effect in the body. Several studies have been carried out to compare the bioequivalence of different Flupentixol formulations:

  • A study compared new film-coated tablet formulations (0.5 mg, 1 mg, and 5 mg) with the marketed coated tablet formulations of Flupentixol[4].
  • Another study evaluated the bioequivalence of Flupentixol/Melitracen combination tablets in both fasted and fed conditions[3].

These studies help ensure that patients receive consistent and effective treatment regardless of the specific formulation they are prescribed.

Combination with Other Medications

Flupentixol is sometimes combined with other medications to enhance its therapeutic effects:

  • Flupentixol and Melitracen: This combination has been studied for its effectiveness in treating emotional disorders. Melitracen is a tricyclic antidepressant that complements the antipsychotic properties of Flupentixol[2].

Administration and Dosage

The administration of Flupentixol varies depending on the formulation:

  • Oral tablets: These are typically taken once daily, with dosages ranging from 0.5 mg to 5 mg, depending on the patient’s condition and response to treatment[4].
  • Injectable form (Flupentixol Decanoate): This is administered as an intramuscular injection, usually every 2-4 weeks, depending on the patient’s needs[1].

It’s important to note that dosage and administration should always be determined by a healthcare professional based on individual patient needs and response to treatment.

Potential Side Effects

While specific side effects were not detailed in the provided clinical trial information, it’s important for patients to be aware that all medications can have potential side effects. Common side effects of antipsychotic medications like Flupentixol may include:

  • Drowsiness or sedation
  • Dry mouth
  • Constipation
  • Weight gain
  • Dizziness

Patients should always discuss potential side effects with their healthcare provider and report any unusual symptoms they experience while taking Flupentixol.

Study Focus Drug Formulation Conditions Studied Key Outcomes Measured
Substance Abuse Flupentixol Decanoate Methamphetamine dependence Methamphetamine use reduction
Emotional Disorders Flupentixol and Melitracen tablets Non-random emotional disorders Effectiveness in reducing emotional symptoms
Bioequivalence Film-coated vs. coated tablets Healthy subjects Area under plasma concentration-time curve, Maximum observed concentration
Dosage Comparison 0.5 mg, 1 mg, 5 mg tablets Healthy subjects Pharmacokinetic parameters

FAQ

  • What conditions are being studied in these clinical trials using Flupentixol Decanoate? The clinical trials are studying various conditions, including substance-related disorders (specifically methamphetamine dependence), emotional disorders, and neurologic disorders. Some trials are also focused on bioequivalence studies in healthy subjects.
  • What is the purpose of the bioequivalence studies? The bioequivalence studies aim to compare different formulations of Flupentixol, such as film-coated tablets and coated tablets, to ensure they have similar effects in the body. This helps in developing new formulations that are as effective as existing ones.
  • How is Flupentixol being used in combination with other drugs in some trials? In one trial, Flupentixol is being used in combination with Melitracen to treat emotional disorders. This combination is being studied for its effectiveness in managing different types of non-random emotional disorders.
  • What are the main outcomes being measured in these trials? The trials measure various outcomes, including drug use reduction (for substance abuse studies), improvement in emotional symptoms, and pharmacokinetic parameters like the area under the plasma concentration-time curve and maximum observed concentration in bioequivalence studies.
  • Are these trials only conducted on patients with specific conditions? While some trials focus on patients with specific conditions like substance abuse or emotional disorders, others are conducted on healthy volunteers, particularly for bioequivalence studies to compare different drug formulations.

Ongoing Clinical Trials on Flupentixol Decanoate

  • Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy Spain

  • Study on Reducing Antipsychotic Dose vs. Maintenance Treatment for Patients with Schizophrenia Using Haloperidol Decanoate, Risperidone, and Amisulpride

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Bioequivalence: A state where two medications with the same active ingredient are considered to have the same effect on the body. This is important when comparing different formulations or brands of a drug.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated. This helps determine the right dosage and timing of medication.
  • Flupentixol Decanoate: A long-acting antipsychotic medication used to treat various mental health conditions. It's being studied for its potential in treating substance abuse and emotional disorders.
  • Methamphetamine dependence: A condition where a person becomes physically or psychologically dependent on methamphetamine, a powerful and highly addictive stimulant drug.
  • Involuntary emotional expression disorder (IEED): A neurological condition characterized by sudden, uncontrollable episodes of crying, laughing, or other emotional expressions that don't match how the person actually feels.
  • Area under the plasma concentration-time curve (AUC): A measure used in pharmacology to show the total exposure to a drug over time. It helps determine how much of the drug is in the body and for how long.
  • Maximum observed concentration (Cmax): The highest concentration of a drug observed in the blood after it's been administered. This helps determine how much of the drug reaches the bloodstream and how quickly.

References

  1. https://clinicaltrials.gov/study/NCT00000241
  2. https://clinicaltrials.gov/study/NCT04970667
  3. https://clinicaltrials.gov/study/NCT03472651
  4. https://clinicaltrials.gov/study/NCT02660840